QuidelOrtho (QDEL) to Release Earnings on Tuesday

QuidelOrtho (NASDAQ:QDEL - Get Free Report) is expected to be announcing its earnings results after the market closes on Tuesday, February 11th. Analysts expect the company to announce earnings of $1.07 per share for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.

QuidelOrtho (NASDAQ:QDEL - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.85 EPS for the quarter, beating analysts' consensus estimates of $0.30 by $0.55. The company had revenue of $727.00 million during the quarter, compared to the consensus estimate of $642.16 million. QuidelOrtho had a positive return on equity of 4.24% and a negative net margin of 66.25%. The company's quarterly revenue was down 2.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.90 EPS. On average, analysts expect QuidelOrtho to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

QuidelOrtho Price Performance

Shares of NASDAQ QDEL traded up $0.79 during mid-day trading on Friday, reaching $42.89. The company had a trading volume of 767,486 shares, compared to its average volume of 852,359. QuidelOrtho has a 1-year low of $29.74 and a 1-year high of $69.83. The stock has a market cap of $2.88 billion, a PE ratio of -1.54 and a beta of 0.08. The company has a current ratio of 1.38, a quick ratio of 0.81 and a debt-to-equity ratio of 0.68. The company has a 50-day moving average price of $43.17 and a two-hundred day moving average price of $42.20.

Insiders Place Their Bets

In other news, CEO Brian J. Blaser purchased 6,033 shares of the business's stock in a transaction dated Wednesday, December 11th. The stock was bought at an average cost of $41.42 per share, with a total value of $249,886.86. Following the purchase, the chief executive officer now directly owns 6,033 shares of the company's stock, valued at approximately $249,886.86. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Carlyle Group Inc. sold 8,260,183 shares of the business's stock in a transaction that occurred on Thursday, November 21st. The shares were sold at an average price of $35.31, for a total value of $291,667,061.73. The disclosure for this sale can be found here. Insiders own 1.00% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Jefferies Financial Group initiated coverage on QuidelOrtho in a report on Tuesday, December 10th. They set a "hold" rating and a $43.00 price objective on the stock. Citigroup upgraded shares of QuidelOrtho from a "neutral" rating to a "buy" rating and upped their price target for the company from $44.00 to $50.00 in a research report on Wednesday, December 11th. StockNews.com raised shares of QuidelOrtho from a "hold" rating to a "buy" rating in a research note on Friday. Finally, William Blair reissued a "market perform" rating on shares of QuidelOrtho in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $53.43.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.